OneMedNet Corporation announced that its regulatory‑grade real‑world data set was instrumental in mlHealth 360’s successful submission to the U.S. Food and Drug Administration for 510(k) clearance of the Scaida BrainCT‑ICH AI software, which detects intracranial hemorrhage from head CT scans in approximately 5.97 seconds. The clearance authorizes the product to market as a medical device that can provide rapid, accurate hemorrhage detection for acute stroke and trauma care.
The FDA approval underscores the value of OneMedNet’s iRWD platform, which delivers de‑identified imaging and electronic health record data that meet FDA regulatory standards. By providing high‑quality, longitudinal data, OneMedNet enabled mlHealth to validate and submit the AI model without the need for proprietary data acquisition, accelerating the product’s regulatory pathway and demonstrating the growing importance of real‑world data in FDA submissions.
For OneMedNet, the clearance validates its data‑curation business model and expands its customer base in the regulated AI space. The company has formed strategic partnerships with Palantir and Circle Cardiovascular Imaging to enhance data delivery and subscription revenue, but it continues to face negative margins and declining revenue. The milestone signals that its platform can drive future growth, potentially attracting new clients and investment despite current financial headwinds.
Aaron Green, CEO and President of OneMedNet, said the company is proud to collaborate with mlHealth 360 and to support their efforts in advancing patient care through clinically impactful AI. Kumar Surender Sinwar, CEO of mlHealth 360, noted that partnering with OneMedNet provided “immediate access to high‑quality, regulatory‑grade imaging and clinical data” that was “essential in getting Scaida BrainCT‑ICH to FDA clearance.”
While the fact‑check report did not identify a specific market reaction to the January 22 announcement, broader context shows that OneMedNet’s stock had declined 21.55% year‑to‑date, and earlier gains were tempered by ongoing financial challenges. The clearance may improve investor perception of the company’s data platform, but the company’s negative margins and revenue decline remain concerns.
The FDA clearance highlights the critical role of real‑world data in accelerating AI medical device approvals and positions OneMedNet as a key partner for future AI‑driven medical devices. The event is a significant regulatory milestone that could drive new customer acquisition and strengthen OneMedNet’s competitive position in the growing AI‑healthcare market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.